Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.5
2.7
Journals
Applied Sciences
Special Issues
Application of Targeted Therapy in Cancer Treatment
share announcement

Application of Targeted Therapy in Cancer Treatment

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Biomedical Engineering".

Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 2423

Special Issue Editor

Dr. Carmela Saturnino

E-Mail Website1 Website2
Guest Editor
Department of Science, University of Basilicata, 85100 Potenza, Italy
Interests: medicinal chemistry; membranes; nanoparticles; drug delivery systems
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Even today, novel pharmacological and technological applicative therapies, in the field of cancer treatment, are very current. In particular, much research is focused on direct treatments that could be performed on some forms of solid tumors, potentially without removing them. Therefore, it is useful to discover new synthetic and natural molecules and controlled release systems in which to incorporate them. The antioxidant aspect of these molecules is also important, bearing in mind that reactive species are always responsible for them.

Dr. Carmela Saturnino
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • heterocyclics
  • antioxidant
  • organo-metals

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 16143 KiB  
Article
Computational Analysis of Nanocarriers in the Tumor Microenvironment for the Treatment of Colorectal Cancer
by Esteban Vallejo Morales, Gustavo Suárez Guerrero, Lina M. Hoyos Palacio and Yvon Maday
Appl. Sci. 2023, 13(10), 6248; https://doi.org/10.3390/app13106248 - 19 May 2023
Viewed by 893
Abstract
Colorectal cancer is currently treated by surgical procedures, chemotherapy and radiotherapy; however, these latest treatments are highly aggressive, with side effects that affect the patient’s quality of life. The scientific union has been investigating other more favorable alternatives, such as targeted therapy, which [...] Read more.
Colorectal cancer is currently treated by surgical procedures, chemotherapy and radiotherapy; however, these latest treatments are highly aggressive, with side effects that affect the patient’s quality of life. The scientific union has been investigating other more favorable alternatives, such as targeted therapy, which seeks greater selectivity in the type of target cells. This type of treatment can significantly reduce side effects in the patient. The goal of this research is to computationally visualize the behavior of nanocarriers in the colon tumor microenvironment, as well as their capacity for deepening, selective coupling and differentiating between healthy and cancerous tissue. A group of histological samples of cancerous tissue was selected, based on morphological criteria and the stage of the disease. This was used to elaborate 2D and 3D models to study different cases using artificial vision and computer simulation techniques. The results indicated velocities of the nanocarriers that reached values between 1.40 and 8.69×10−7ms for a time of 3.88 h, with a vectorized deposition efficiency of 1.0 to 4.46%. In addition, selective mating events were achieved at a maximum depth of 4.68 × 10−4 m. This scientific knowledge can contribute to the estimation of the efficacy of the treatment, as well as the assessment for different dosage levels and frequency of drug administration from the studies carried out on the lesion. Full article
(This article belongs to the Special Issue Application of Targeted Therapy in Cancer Treatment)
►▼ Show Figures

Figure 1

17 pages, 2711 KiB  
Article
An Optimized Methodology for Patient-Specific Therapeutic Activity Administration in Liver Radioembolization
by Paulo Ferreira, Francisco P. M. Oliveira, Rui Parafita, Paulo L. Correia, Pedro S. Girão and Durval C. Costa
Appl. Sci. 2022, 12(22), 11669; https://doi.org/10.3390/app122211669 - 17 Nov 2022
Viewed by 1127
Abstract
Radioembolization (RE) with glass microspheres (MS) loaded with Yttrium-90 (90Y) has been used to treat tumors in the liver with some reported success. However, assessing absorbed doses (AD) in the planning tumor volume (PTV) and normal liver volume (NLV) is a [...] Read more.
Radioembolization (RE) with glass microspheres (MS) loaded with Yttrium-90 (90Y) has been used to treat tumors in the liver with some reported success. However, assessing absorbed doses (AD) in the planning tumor volume (PTV) and normal liver volume (NLV) is a key problem to address in RE. In clinical practice, the computation of 90Y activity to be administered follows the manufacturer’s recommendations, which do not consider the specific characteristics of MS deposition in each patient’s liver. Our main aim is to develop a methodology to estimate the optimal activity for each patient treatment. It uses the absorbed dose distribution (ADD) derived from the Technetium-99m (99mTc)-labeled macroaggregated albumin (MAA) obtained from pre-treatment planning single-photon emission computed tomography (SPECT) images. Post-treatment positron emission tomography (PET) images of the 90Y-MS distribution were used to estimate the ADD for treatment verification. Sixteen RE treatments were retrospectively selected. The agreement between the estimated mean AD based on the planning imaging and real post-treatment mean AD was good in PTV with an intraclass correlation coefficient (ICC) of 0.79 and excellent in NLV (ICC = 0.97). The optimization of 90Y activity using pre-defined clinical AD thresholds (<70 Gy in NLV and >80 Gy in PTV) imposed on the PTV and NLV voxels showed remarkably high agreement (ICC = 0.96, p < 0.001) in eleven out of the sixteen RE treatments between SPECT-MAA-based and PET-MS-based optimal activity estimates. In conclusion, under well-controlled conditions, pre-treatment SPECT-MAA imaging predicts well the treatment of ADD. In addition, SPECT-MAA imaging can be used to optimize the 90Y-MS activity to be administered to the liver. Full article
(This article belongs to the Special Issue Application of Targeted Therapy in Cancer Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop